Sarah Kathryn Rouan, Director at NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB), bought 3,350 shares at $1.46 ($5K) on 2019-05-17, disclosed to the SEC on 2019-05-21.
Open-market purchase of $5k NAVB by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Something here stands out, but not much.
| Filing → |
| VKTX | SELL | 2024-02-08 | $701K | — | Filing → |
| VKTX | SELL | 2024-01-19 | $692K | — | Filing → |